<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81743</article-id><article-id pub-id-type="doi">10.7554/eLife.81743</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Antigenic mapping and functional characterization of human new world hantavirus neutralizing antibodies</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-286513"><name><surname>Engdahl</surname><given-names>Taylor B</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6280-4405</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286514"><name><surname>Binshtein</surname><given-names>Elad</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286515"><name><surname>Brocato</surname><given-names>Rebecca L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286516"><name><surname>Kuzmina</surname><given-names>Natalia A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286517"><name><surname>Principe</surname><given-names>Lucia M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286518"><name><surname>Kwilas</surname><given-names>Steven A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0383-3879</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286519"><name><surname>Kim</surname><given-names>Robert K</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286520"><name><surname>Chapman</surname><given-names>Nathaniel S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286521"><name><surname>Porter</surname><given-names>Monique S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-133225"><name><surname>Guardado-Calvo</surname><given-names>Pablo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7292-5270</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-133226"><name><surname>Rey</surname><given-names>FÃ©lix A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9953-7988</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286522"><name><surname>Handal</surname><given-names>Laura S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286523"><name><surname>Diaz</surname><given-names>Summer M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286524"><name><surname>Zagol-Ikapitte</surname><given-names>Irene A</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-312538"><name><surname>Tran</surname><given-names>Minh H</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18107"><name><surname>McDonald</surname><given-names>W Hayes</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262994"><name><surname>Meiler</surname><given-names>Jens</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8945-193X</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286525"><name><surname>Reidy</surname><given-names>Joseph X</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286526"><name><surname>Trivette</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-56156"><name><surname>Bukreyev</surname><given-names>Alexander</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0342-4824</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-286527"><name><surname>Hooper</surname><given-names>Jay W</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-14804"><name><surname>Crowe</surname><given-names>James E</given-names><suffix>Jr.</suffix></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0049-1079</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pathology, Microbiology and Immunology</institution>, <institution>Vanderbilt University</institution>, <addr-line><named-content content-type="city">Nashville</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Vanderbilt Vaccine Center</institution>, <institution>Vanderbilt University Medical Center</institution>, <addr-line><named-content content-type="city">Nashville</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Virology Division</institution>, <institution>United States Army Medical Research Institute of Infectious Diseases</institution>, <addr-line><named-content content-type="city">Ft Detrick</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Pathology</institution>, <institution>The University of Texas Medical Branch at Galveston</institution>, <addr-line><named-content content-type="city">Galveston</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Virology Department</institution>, <institution>Institut Pasteur, CNRS UMR 3569</institution>, <addr-line><named-content content-type="city">Paris</named-content></addr-line>, <country>France</country></aff><aff id="aff6"><institution content-type="dept">Department of Biochemistry</institution>, <institution>Vanderbilt University</institution>, <addr-line><named-content content-type="city">Nashville</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Department of Chemistry</institution>, <institution>Vanderbilt University</institution>, <addr-line><named-content content-type="city">Nashville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-45406"><name><surname>Casadevall</surname><given-names>Arturo</given-names></name><role>Reviewing editor</role><aff><institution>Johns Hopkins Bloomberg School of Public Health</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jay.w.hooper.civ@mail.mil</email> (JH);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>james.crowe@vanderbilt.edu</email> (JC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>27</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e81743</elocation-id><history><date date-type="received"><day>11</day><month>07</month><year>2022</year></date><date date-type="accepted"><day>27</day><month>03</month><year>2023</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81743-v1.pdf"/><abstract><p>Hantaviruses are high-priority emerging pathogens carried by rodents and transmitted to humans by aerosolized excreta or, in rare cases, person-to-person contact. While infections in humans are relatively rare, mortality rates range from 1 to 40% depending on the hantavirus species. There are currently no FDA-approved vaccines or therapeutics for hantaviruses, and the only treatment for infection is supportive care for respiratory or kidney failure. Additionally, the human humoral immune response to hantavirus infection is incompletely understood, especially the location of major antigenic sites on the viral glycoproteins and conserved neutralizing epitopes. Here, we report antigenic mapping and functional characterization for four neutralizing hantavirus antibodies. The broadly neutralizing antibody SNV-53 targets an interface between Gn/Gc, neutralizes through fusion inhibition and cross-protects against the Old World hantavirus species Hantaan virus when administered pre- or post-exposure. Another broad antibody, SNV-24, also neutralizes through fusion inhibition but targets domain I of Gc and demonstrates weak neutralizing activity to authentic hantaviruses. ANDV-specific, neutralizing antibodies (ANDV-5 and ANDV-34) neutralize through attachment blocking and protect against hantavirus cardiopulmonary syndrome (HCPS) in animals but target two different antigenic faces on the head domain of Gn. Determining the antigenic sites for neutralizing antibodies will contribute to further therapeutic development for hantavirus-related diseases and inform the design of new broadly protective hantavirus vaccines.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>5T32GM008320</award-id><principal-award-recipient><name><surname>Engdahl</surname><given-names>Taylor B</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Military Infectious Diseases Program</institution></institution-wrap></funding-source><award-id>MI210048</award-id><principal-award-recipient><name><surname>Hooper</surname><given-names>Jay W</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>S10 OD030292</award-id><principal-award-recipient><name><surname>Crowe</surname><given-names>James E</given-names><suffix>Jr.</suffix></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>James E Crowe, has served as a consultant for Luna Labs USA, Merck Sharp &amp; Dohme Corporation, Emergent Biosolutions, GlaxoSmithKline and BTG International Inc, is a member of the Scientific Advisory Board of Meissa Vaccines, a former member of the Scientific Advisory Board of Gigagen (Grifols) and is founder of IDBiologics. The laboratory of J.E.C. received unrelated sponsored research agreements from AstraZeneca, Takeda, and IDBiologics during the conduct of the study..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal challenge studies were conducted in the ABSL-4 facility of the Galveston National Laboratory. The animal protocol for testing of mAbs in hamsters was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Medical Branch at Galveston (UTMB) (protocol #1912091).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript.</p></sec><supplementary-material><ext-link xlink:href="elife-81743-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>